Join advanced therapies stakeholders to take stock of the first half of 2020 and the short and long term implications of the ongoing COVID-19 pandemic. Hear an update on FDA regulatory guidance for manufacturers, take part in a virtual Q&A, and gain insight on current consortia initiatives and priorities for cell and gene therapy manufacturing and commercial development.
Speakers
Peter Marks MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)
Steven Goodman
Head of Drug Product Manufacturing
Bluebird Bio
Mark Plavsic
Chief Technology Officer and Head of Nonclinical Development
LYSOGENE
Kelvin H. Lee
Institute Director
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Craig Malzahn
Head of Technical Operations
REGENXBIO Inc.
Rick Silva PhD
Executive Director, Clinical, Translation and Industry Collaborations
Texas A&M Health Science Center
Vlad Hogenhuis
Chief Operating Officer (fmr.)
Ultragenyx
Michael Lehmicke
Director, Science and Industry Affairs
Alliance for Regenerative Medicine
Create New Relationships that Deliver the Highest Value for your Current Networking Needs with:
LIVE event. No pre-recorded sessions
Social: Real-time Q&A between speakers and attendees during sessions, live polling, and direct messaging capability between attendees
Enhanced Networking: automated matchmaking suggestions based on your goals & interests. Use our virtual “meeting rooms” and set up 1:1 meetings.
Breakout networking rooms and room “hopping” capability
Brand Advisory Board
Laurie Smaldone
CMO/CSO
NDA Group
John Balchunus
Workforce Director
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Vera Hoffman
CEO & Co Founder
Reveal Pharma
John McShane
Managing Director
Validant
Anton Xavier
Founder and CEO
K9 Biotech
James Zanewicz
Chief Business Officer
Tulane University
In Partnership With :
QUESTIONS?
Contact us: 1-800-882-8684
Email: enquiry@iqpc.com
©2024 IQPC. All rights reserved.
